Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22. - Vasu S; Denlinger N; Song NJ; Elsberry D; Zhao Q; Yu L; Bezerra E; Szuminski N; Schneider D; Dash P; Wirthlin L; Epperla N; et al. (Research square, 2026)